Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint

US-based Amgen and its subsidiary, Onyx Pharmaceuticals, have reported data from the Phase III ASPIRE trial of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone to treat patients with relapsed multiple myeloma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news